Myeloperoxidase as a Promising Therapeutic Target after Myocardial Infarction
Antioxidants · 28.06.2024 · 13 (7) · 788
DOI: 10.3390/antiox13070788 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antioxidants, online erschienen am 28.06.2024. Verfasst von Maxwell Quinn und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cardiometabolic Disease Research Group, School of Biomedical Sciences, Faculty of Medicine & Health, University of New South Wales, Sydney, NSW 2052,…. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 233 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian Medical Research Future Fund, National Health and Medical Research Council, Heart Foundation.
Abstract (Originalsprache)
Coronary artery disease (CAD) and myocardial infarction (MI) remain leading causes of death and disability worldwide. CAD begins with the formation of atherosclerotic plaques within the intimal layer of the coronary arteries, a process driven by persistent arterial inflammation and oxidation. Myeloperoxidase (MPO), a mammalian haem peroxidase enzyme primarily expressed within neutrophils and monocytes, has been increasingly recognised as a key pro-inflammatory and oxidative enzyme promoting the development of vulnerable coronary atherosclerotic plaques that are prone to rupture, and can precipitate a MI. Mounting evidence also implicates a pathogenic role for MPO in the inflammatory process that follows a MI, which is characterised by the rapid infiltration of activated neutrophils into the damaged myocardium and the release of MPO. Excessive and persistent cardiac inflammation impairs normal cardiac healing post-MI, resulting in adverse cardiac outcomes and poorer long-term cardiac function, and eventually heart failure. This review summarises the evidence for MPO as a significant oxidative enzyme contributing to the inappropriate inflammatory responses driving the progression of CAD and poor cardiac healing after a MI. It also details the proposed mechanisms underlying MPO’s pathogenic actions and explores MPO as a novel therapeutic target for the treatment of unstable CAD and cardiac damage post-MI.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cardiometabolic Disease Research Group, School of Biomedical Sciences, Faculty of Medicine & Health, University of New South Wales, Sydney, NSW 2052, Australia.
ORCID-Profile: Richard Y K Zhang, Kerry-Anne Rye
Förderung
- Australian Medical Research Future Fund
- National Health and Medical Research Council
- Heart Foundation
Zitieren
APA
Quinn, M., Zhang, R. Y. K., Bello, I., Rye, K. A., & Thomas, S. R. (2024). Myeloperoxidase as a Promising Therapeutic Target after Myocardial Infarction. Antioxidants, 13(7), 788. https://doi.org/10.3390/antiox13070788
Vancouver
Quinn M, Zhang RYK, Bello I, Rye KA, Thomas SR. Myeloperoxidase as a Promising Therapeutic Target after Myocardial Infarction. Antioxidants. 2024;13(7):788. doi:10.3390/antiox13070788
BibTeX
@article{Quinn2024,
author = {Quinn, Maxwell and Zhang, Richard Y K and Bello, Idris and Rye, Kerry-Anne and Thomas, Shane R},
title = {Myeloperoxidase as a Promising Therapeutic Target after Myocardial Infarction},
journal = {Antioxidants},
year = {2024},
volume = {13},
number = {7},
pages = {788},
doi = {10.3390/antiox13070788}
}
EUVIMED